ERBB2 and neoplasm: Although a previous study presented an MRI-based signature, which could noninvasively characterize HER2-positive tumor biological factors and estimate the response to HER2-targeted neoadjuvant therapy, the small size sample and highly heterogeneous data limited the application [29].